Theta Burst Stimulation as a Tool to Decrease Drinking in Treatment-seeking Alcohol Users
Key facts
- Who runs it
- Wake Forest University Health Sciences
- Where
- Winston-Salem, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 147 people enrolled
- Started
- 26 May 2020
- Ended
- 9 Feb 2026
- Type of study
- Interventional, 4 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- Real TBS to the vmPFC
- Sham TBS to the vmPFC
- Real TBS to the dlPFC
- Sham TBS to the dlPFC
- Record updated
- 2 June 2026
Who can take part
- Age
- 21 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Age 21- 75
- Meets the DSM V criteria for having a current AUD, determined by DSM-V criteria, using the Structured Clinical Interview for DSM-V
- Has an AUDIT score above 8 (such that they are at least Medium Risk drinkers according to criteria)
Who cannot take part
- Is currently taking or initiates a medication known to affect alcohol intake and/or craving (e.g., disulfiram. naltrexone, acamprosate, topiramate). [Note: This exclusionary criterion is for scientific rather than safety or patient comfort reasons]
- Expects a change in their medical history in the next 6 months that would impair their participation in this study [e.g. expected medical procedure, planned pregnancy, initiation of new medication]
- Meets DSM V criteria for schizoaffective disorder. [Note: The inclusion of subjects with affective and anxiety disorders is essential because of the marked frequency of the co-existence of mood and other anxiety disorders among patients with AUD at large
- Is at elevated risk of seizure (i.e., has a history of seizures, is currently prescribed medications known to lower seizure threshold and has had a change in their medication)
- Is currently enrolled in another form of treatment for alcohol use disorder (This is for scientific reasons to clarify the role of TMS as a treatment agent)
- History of traumatic brain injury resulting in hospitalization, loss of consciousness for more than 10 minutes, and/or having ever been informed he/she has an epidural, subdural, or subarachnoid hemorrhage
- Any psychoactive substance use (except marijuana and nicotine) within the last 30 days by self-report
- Has current suicidal ideation or homicidal ideation
- Females of childbearing potential who are pregnant (by urine HCG), planning to become pregnant, nursing, or who are not using a reliable form of birth control
- Suffers from chronic migraines (more than 50% of the days in a month)
- Does not meet safety criteria for MRI and TMS
- Not able to read and understand questionnaires, assessments, and the informed consent
- Clinical Intake Withdrawal Assessment (CIWA) >5 (to prevent delivering TMS to individuals in withdrawal
Where in United States
- Wake Forest School of MedicineWinston-Salem, United States
About the trial
What the trial wants to find out
There is growing interest in the utilization of transcranial magnetic stimulation (TMS) as a novel, non-pharmacologic approach to decreasing alcohol use among treatment-seeking individuals with Alcohol Use Disorder (AUD). The results of this study will be used to determine which of the 2 proposed TMS strategies has a larger effect on drinking behavior (% days abstinent, % heavy drinking days) as well as alcohol cue-reactivity in a 4 month period. These data will pave the way for TMS to be used as an innovative, new treatment option for individuals with AUD.
The 4 groups in the trial
- Real TBS to the mPFCTreatment being tested
Thirty sessions of real Theta Burst Stimulation (TBS) will be delivered to the left medial prefrontal cortex (mPFC)
Treatment: Real TBS to the vmPFC
- Sham TBS to the mPFCSham treatment, for comparison
Thirty sessions of sham Theta Burst Stimulation (TBS) will be delivered to the left medial prefrontal cortex (mPFC)
Treatment: Sham TBS to the vmPFC
- Real TBS to the dlPFCTreatment being tested
Thirty sessions of real Theta Burst Stimulation (TBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC)
- Sham TBS to the dlPFCSham treatment, for comparison
Thirty sessions of sham Theta Burst Stimulation (TBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Record updated
- 2 June 2026